Last reviewed · How we verify
TMC125, Darunavir; Ritonavir
TMC125, Darunavir; Ritonavir is a combination of HIV protease inhibitors that work by blocking the protease enzyme, preventing the maturation of viral particles.
TMC125, Darunavir; Ritonavir is a combination of HIV protease inhibitors that work by blocking the protease enzyme, preventing the maturation of viral particles. Used for Treatment of HIV-1 infection in treatment-experienced adult patients, Treatment of HIV-1 infection in treatment-naive adult patients.
At a glance
| Generic name | TMC125, Darunavir; Ritonavir |
|---|---|
| Sponsor | Tibotec, Inc |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Darunavir and Ritonavir are both HIV protease inhibitors that target the protease enzyme, which is essential for the maturation of viral particles. By blocking this enzyme, they prevent the virus from replicating and reduce the viral load in the body.
Approved indications
- Treatment of HIV-1 infection in treatment-experienced adult patients
- Treatment of HIV-1 infection in treatment-naive adult patients
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- B-free Multistage Trial (PHASE4)
- Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) (PHASE1)
- Optimizing Treatment for Treatment-Experienced, HIV-Infected People (PHASE3)
- CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TMC125, Darunavir; Ritonavir CI brief — competitive landscape report
- TMC125, Darunavir; Ritonavir updates RSS · CI watch RSS
- Tibotec, Inc portfolio CI